KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Vir Biotechnology (VIR) Preferred Shares Issued (2018 - 2019)

Vir Biotechnology's Preferred Shares Issued history spans 2 years, with the latest figure at -$7000.0 for Q2 2019.

On a quarterly basis, Preferred Shares Issued fell 100.05% to -$7000.0 in Q2 2019 year-over-year; TTM through Dec 2019 was $317.3 million, a N/A change, with the full-year FY2019 number at $317.3 million, up 2126.29% from a year prior.
Preferred Shares Issued hit -$7000.0 in Q2 2019 for Vir Biotechnology, down from $317.3 million in the prior quarter.
Over the last five years, Preferred Shares Issued for VIR hit a ceiling of $317.3 million in Q1 2019 and a floor of -$7000.0 in Q2 2019.